Dilaforette is a drug development company developing a heparan sulphate mimetic, sevuparin, a proprietary drug derived from heparin. Sevuparin is an innovative, disease-modifying polysaccharide drug, with extensive world-wide IP protection.
Sevuparin is intended to be used as an anti-adhesive therapy and has therefore been designed to retain the anti-adhesives effects of heparin, while reducing the anti-coagulant properties. Sevuparin, with demonstrated strong anti-adhesive effects, has the potential to be of clinical use in several therapeutic conditions. Dilaforette is currently developing sevuparin for acute vaso-occlusive crises in sickle cell disease as the initial indication as well as for malaria.
Dilaforette, a Swedish drug development company, founded by leading scientists in malaria from Karolinska Institute as well as leading experts in the field of heparin and drug development from Uppsala University and the Swedish pharmaceutical industry together with Karolinska Innovation AB.